AdvanCell reports 80% PSA response with ADVC001 in updated Phase 1 prostate cancer study
AdvanCell reports an 80% PSA response and 11.2-month median rPFS with ADVC001. Small Phase 1 numbers leave important efficacy questions.
Pharma & Biotech
Pharma & Biotech
Why investors just put $315m behind AdvanCell’s prostate cancer alpha therapy
AdvanCell’s US$315 million Series D backs ADVC001 trials and Lead-212 manufacturing, but Phase 2 evidence remains the decisive test.